We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Simultaneous Determination of Amlodipine and its Counterion Besylate
Product News

Simultaneous Determination of Amlodipine and its Counterion Besylate

Simultaneous Determination of Amlodipine and its Counterion Besylate
Product News

Simultaneous Determination of Amlodipine and its Counterion Besylate


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Simultaneous Determination of Amlodipine and its Counterion Besylate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Thermo Fisher Scientific has developed a simple, rapid, reliable, and accurate high-performance liquid chromatography (HPLC) method for the simultaneous determination of amlodipine and besylate in an amlodipine besylate drug substance.

Application Note 1087: Simultaneous Determination of Amlodipine and Its Counterion Besylate by HPLC demonstrates that this method requires only 8 minutes per analysis using a column designed for pharmaceutical analysis and ultraviolet detection.

In addition, combining the analysis of the active pharmaceutical ingredient (API) and counterion into a single method saves times, reduces mobile phase consumption, and minimizes waste.

Amlodipine besylate is a commonly prescribed drug product. During the drug manufacturing process, HPLC techniques are frequently used to analyze the API, but often lack the sensitivity to reliably identify the counterion.

Although the current U.S. Pharmacopeia monograph for determining amlodipine besylate describes an HPLC method for separating the API, it has no method to determine the besylate counterion.

Thus, this new approach gives drug manufacturers the ability to simultaneously determine both amlodipine and its counterion besylate in a single method.

Advertisement